1-800-526-8630
Detailed overview of the SPMS disease area including a definition of the area, etiology, symptoms and disease diagnosis.
This report provides an overview of the secondary progressive multiple sclerosis (SPMS) disease in detail. The report starts with the basic definition, causes and symptoms of Multiple Sclerosis and further details the types of Multiple Sclerosis diseases. The report elaborates on the Secondary Progressive Multiple Sclerosis disease indication starting from the definition and the causes of the SPMS indication.
The report covers further details on the profile of an SPMS patient, symptoms of SPMS patients and disease progression in an SPMS patient. The report further highlights the multiple methods through which the patient can be diagnosed for SPMS.
1. Multiple Sclerosis Definition
2 Types of Multiple Sclerosis
a. Relapsing Remitting MS
b. Secondary Progressive MS
c. Primary Progressive MS
d. Progressive Relapsing MS
3. Secondary Progressive Relapsing MS Defined
4. Causes of SPMS
5. Profile of SPMS Patient
6. Symptoms of SPMS
7. Disease progression and impact on QoL
8. Disease Diagnosis
a. Disease diagnosis through symptoms
b. Disease diagnosis through medical test
9. Disease Epidemiology
a. US Epidemiology
b. UK Epidemiology
c. Germany Epidemiology
d. Italy Epidemiology
e. France Epidemiology
f. Spain Epidemiology
g. Japan Epidemiology
10. Factors impacting a physician’s prescription decision
a. Efficacy
b. Tolerability and Safety
c. Monitoring Requirements
d. Pricing and Reimbursement
11. Disease Modifying Therapies for SPMS
a. Laquinimod
i. About the Product
ii. Patent and Trial Details
iii. Impact of Laquinimod
b. Lemtrada
i. About the Product
ii. Patent and Trial Details
iii. Impact of Lemtrada
c. Masitinib
i. About the Product
ii. Patent and Trial Details
iii. Impact of Masitinib
d. Ocrelizumab
i. About the Product
ii. Patent and Trial Details
iii. Impact of Ocrelizumab
e. Tysabri
i. About the Product
ii. Patent and Trial Details
iii. Impact of Tysabri
f. Siponimod
i. About the Product
ii. Patent and Trial Details7
iii. Impact of Siponimod
g. Zinbryta
i. About the Product
ii. Patent and Trial Details
iii. Impact of Zinbryta
h. Mitoxantrone
i. About the Product
ii. Patent and Trial Details
iii. Impact of Mitoxantrone
i. Ponesimod
i. About the Product
ii. Patent and Trial Details
iii. Impact of Ponesimod
12. Drug Attribute Analysis
a. Laquinimod
b. Lemtrada
c. Masitinib
d. Ocrelizumab
e. Ponesimod
f. Siponimod
g. Tysabri
h. Zinbryta
i. Mitoxantrone
13. Other Pipeline Products
a. Number of Pipeline Products phase wise
b. Number of Companies having other pipeline products phase wise
14. SPMS Market Sizing
a. Laquinimod
i. Value sales in SPMS indication
ii. Patient numbers in SPMS indication
iii. Value sales by key geographies/countries
iv. Patient numbers by key geographies/countries
b. Lemtrada
i. Value sales in SPMS indication
ii. Patient numbers in SPMS indication
iii. Value sales by key geographies/countries
iv. Patient numbers by key geographies/countries
c. Masitinib
i. Value sales in SPMS indication
ii. Patient numbers in SPMS indication
iii. Value sales by key geographies/countries
iv. Patient numbers by key geographies/countries
d. Ocrelizumab
i. Value sales in SPMS indication
ii. Patient numbers in SPMS indication
iii. Value sales by key geographies/countries
iv. Patient numbers by key geographies/countries
e. Ponesimod
i. Value sales in SPMS indication
ii. Patient numbers in SPMS indication
iii. Value sales by key geographies/countries
iv. Patient numbers by key geographies/countries
f. Siponimod
i. Value sales in SPMS indication
ii. Patient numbers in SPMS indication
iii. Value sales by key geographies/countries
iv. Patient numbers by key geographies/countries
g. Tysabri
i. Value sales in SPMS indication
ii. Patient numbers in SPMS indication
iii. Value sales by key geographies/countries
iv. Patient numbers by key geographies/countries
h. Zinbryta
i. Value sales in SPMS indication
ii. Patient numbers in SPMS indication
iii. Value sales by key geographies/countries
iv. Patient numbers by key geographies/countrie
15. Market Sizing Country Wise
a. Global
i. Value sales by Brand
ii. Patient numbers by Brand
b. US
i. Value sales by Brand
ii. Patient numbers by Brand
c. Germany
i. Value sales by Brand
ii. Patient numbers by Brand
d. France
i. Value sales by Brand
ii. Patient numbers by Brand
e. Italy
i. Value sales by Brand
ii. Patient numbers by Brand
f. Spain
i. Value sales by Brand
ii. Patient numbers by Brand
g. UK
i. Value sales by Brand
ii. Patient numbers by Brand6
h. Canada
i. Value sales by Brand
ii. Patient numbers by Brand
i. Australia
i. Value sales by Brand
ii. Patient numbers by Brand
LOADING...
